

Shyh-Han Tan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1557276/publications.pdf>

Version: 2024-02-01

45
papers

2,733
citations

257357

24
h-index

276775

41
g-index

46
all docs

46
docs citations

46
times ranked

3187
citing authors

#	ARTICLE	IF	CITATIONS
1	ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 432-441.	2.1	338
2	SUMO-1 targets RanGAP1 to kinetochores and mitotic spindles. <i>Journal of Cell Biology</i> , 2002, 156, 595-602.	2.3	259
3	ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 228-237.	2.0	227
4	TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. <i>Oncogene</i> , 2008, 27, 5348-5353.	2.6	218
5	The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. <i>Journal of Virology</i> , 1994, 68, 6411-6420.	1.5	182
6	Efficient and Rapid Affinity Purification of Proteins Using Recombinant Fusion Proteases. <i>Nature Biotechnology</i> , 1994, 12, 601-605.	9.4	133
7	SUSP1 antagonizes formation of highly SUMO2/3-conjugated species. <i>Journal of Cell Biology</i> , 2006, 174, 939-949.	2.3	131
8	During negative regulation of the human papillomavirus-16E6 promoter, the viral E2 protein can displace Sp1 from a proximal promoter element. <i>Nucleic Acids Research</i> , 1992, 20, 251-256.	6.5	128
9	YY1 represses human papillomavirus type 16 transcription by quenching AP-1 activity. <i>Journal of Virology</i> , 1996, 70, 6529-6539.	1.5	123
10	Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells. <i>Cancer Research</i> , 2008, 68, 236-248.	0.4	96
11	Signal transducer and activator of transcription 5A/B in prostate and breast cancers. <i>Endocrine-Related Cancer</i> , 2008, 15, 367-390.	1.6	95
12	ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer—a comparative study of two monoclonal antibodies. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 165-169.	2.0	79
13	Nuclear Matrix Attachment Regions of Human Papillomavirus Type 16 Repress or Activate the E6 Promoter, Depending on the Physical State of the Viral DNA. <i>Journal of Virology</i> , 2000, 74, 2489-2501.	1.5	68
14	A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. <i>EBioMedicine</i> , 2015, 2, 1957-1964.	2.7	61
15	Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1255.	1.8	50
16	Expression and regulation of the mammalian SUMO—E1 enzyme. <i>FASEB Journal</i> , 2001, 15, 1825-1827.	0.2	46
17	Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth. <i>Cancer Research</i> , 2018, 78, 3659-3671.	0.4	44
18	Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody. <i>Journal of Cancer</i> , 2010, 1, 197-208.	1.2	44

#	ARTICLE	IF	CITATIONS
19	Nuclear Matrix Attachment Regions of Human Papillomavirus Type 16 Point toward Conservation of These Genomic Elements in All Genital Papillomaviruses. <i>Journal of Virology</i> , 1998, 72, 3610-3622.	1.5	39
20	Androgen-Regulated and Highly Tumorigenic Human Prostate Cancer Cell Line Established from a Transplantable Primary CWR22 Tumor. <i>Clinical Cancer Research</i> , 2008, 14, 6062-6072.	3.2	32
21	Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2017, 15, 1308-1317.	1.5	31
22	ERG oncogene modulates prostaglandin signaling in prostate cancer cells. <i>Cancer Biology and Therapy</i> , 2011, 11, 410-417.	1.5	30
23	Prostate cancer marker panel with single cell sensitivity in urine. <i>Prostate</i> , 2015, 75, 969-975.	1.2	26
24	Loss of the NKX3.1 tumor suppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. <i>BMC Cancer</i> , 2014, 14, 16.	1.1	25
25	Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. <i>Journal of Translational Medicine</i> , 2015, 13, 54.	1.8	23
26	N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 2037-2046.	1.2	22
27	Evaluation of ERG responsive proteome in prostate cancer. <i>Prostate</i> , 2014, 74, 70-89.	1.2	21
28	A Transcriptional Initiator Overlaps with a Conserved YY1 Binding Site in the Long Control Region of Human Papillomavirus Type 16. <i>Virology</i> , 2003, 305, 486-501.	1.1	19
29	ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 126-131.	2.0	17
30	ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. <i>Scientific Reports</i> , 2017, 7, 1109.	1.6	17
31	Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 713-726.	1.9	16
32	Prognostic features of Annexin A2 expression in prostate cancer. <i>Pathology</i> , 2021, 53, 205-213.	0.3	15
33	Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. <i>Genes and Cancer</i> , 2017, 7, 394-413.	0.6	14
34	ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 368-379.	1.5	12
35	Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence. <i>Oncotarget</i> , 2019, 10, 6466-6483.	0.8	10
36	Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression. <i>Scientific Reports</i> , 2022, 12, 5404.	1.6	10

#	ARTICLE	IF	CITATIONS
37	ERG oncoprotein expression in prostate carcinoma patients of different ethnicities. <i>Molecular and Clinical Oncology</i> , 2015, 3, 23-30.	0.4	8
38	Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. <i>Genes and Cancer</i> , 2014, 5, 273-284.	0.6	8
39	Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes. <i>Nature Communications</i> , 2022, 13, 1361.	5.8	8
40	ERG Monoclonal Antibody in the Diagnosis and Biological Stratification of Prostate Cancer: Delineation of Minimal Epitope, Critical Residues for Binding, and Molecular Basis of Specificity. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2014, 33, 201-208.	0.8	7
41	Abstract 2565: Detection of ETV1 expression in human prostate tissue specimens using a novel and highly specific rabbit monoclonal antibody. , 2021, , .		0
42	Abstract 2074: Germline mutation landscape of all DNA repair genes in African American prostate cancer patients. , 2021, , .		0
43	Highlights from the prostate cancer genome report. <i>Asian Journal of Andrology</i> , 2011, 13, 659-660.	0.8	0
44	Abstract 3805: Immunologic transcript and cell type evaluation of prostate tumors from a military cohort of African American and Caucasian American patients. <i>Cancer Research</i> , 2022, 82, 3805-3805.	0.4	0
45	Abstract 2220: Immunohistochemical detection of prostate cancer heterogeneity by using ETS and PTEN monoclonal antibodies. <i>Cancer Research</i> , 2022, 82, 2220-2220.	0.4	0